References
- Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. 45(2), 104–114 (2004).
- Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 61(2), 105–123 (2009).
- Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: a historical overview and future directions. Psychiatry Clin. Neurosci. 64, 341–357 (2010).
- Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog. Neurobiol. doi:10.1016/j.pneurobio.2012.09.001 (2012) (Epub ahead opf print).
- Liu X, Chan CB, Jang SW et al. A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J. Med. Chem. 53, 8274–8286 (2010).
- Shimizu E, Hashimoto K, Okamura N et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients without or with antidepressants. Biol. Psychiatry 54, 70–75 (2003).
- Hashimoto K. BDNF variant linked to anxiety-related behaviors. Bioessays 29(2), 116–119 (2007).
- Yoshida T, Ishikawa M, Iyo M, Hashimoto K. Serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in healthy subjects. Open Clin. Chem. J. 5, 7–12 (2012).
- Yoshida T, Ishikawa M, Niitsu T et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS ONE 7(8), e42676 (2012).
- Lesort M, Tucholski J, Miller ML, Johnson GV. Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog. Neurobiol. 61(5), 439–463 (2000).
- Jeitner TM, Pinto JT, Krasnikov BF, Horswill M, Cooper AJL. Transglutaminases and neurogeneration. J. Neurochem. 109 (Suppl. 1), 160–166 (2009).
- De Vivo G, Gentile V. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 7(4), 370–375 (2008).
- Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann. Intern. Med. 147(4), 242–250 (2007).
- Borrell-Pagès M, Canals JM, Cordelières FP et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116(5), 1410–1424 (2006).
- Pillai A, Veeranan-Karmegam R, Dhandapani KM, Mahadik SP. Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex. J. Neurochem. 107(4), 941–951 (2008).
- Kutiyanawalla A, Terry AV Jr, Pillai A. Cysteamine attenuates the decreases in TrkB protein levels and the anxiety/depression-like behaviors in mice induced by corticosterone treatment. PLoS ONE 6(10), e26153 (2011).
- Dai Y, Dudek NL, Li Q, Muma NA. Phospholipase C, Ca2+, and calmodulin signaling are required for 5-HT2A receptor-mediated transamidation of Rac1 by transglutaminase. Psychopharmacology (Berl.) 213(2–3), 403–412 (2011).
- Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol. Psychiatry 72(7), 537–547 (2012).
- Autry AE, Adachi M, Nosyreva E et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354), 91–95 (2011).
Website
- Press release from Georgia Health Sciences University. Studies seek better understanding and treatment of depression. http://news.georgiahealth.edu/archives/6158 (Accessed 14 August 2012)